

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3447641

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Dale Porter	06/21/2013
Caroline Emery	06/26/2013
Lujian Tan	06/18/2013
Padmaja Yerramilli-Rao	07/08/2013
RECEIVING PARTY DATA	
Name:	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Street Address:	250 MASSACHUSETTS AVENUE
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14647939
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(612) 337-5070
Email:	apsi@fr.com
Correspondent Name:	ANGELA D. FOLLETT
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	41357-0022US1
NAME OF SUBMITTER:	JILL A. WRIGHT
SIGNATURE:	/Jill A. Wright/
DATE SIGNED:	07/21/2015
Total Attachments: 18	
source=61755520#page1.tif	
source=61755520#page2.tif	

source=61755520#page3.tif
source=61755520#page4.tif
source=61755520#page5.tif
source=61755520#page6.tif
source=61755520#page7.tif
source=61755520#page8.tif
source=61755520#page9.tif
source=61755520#page10.tif
source=61755520#page11.tif
source=61755520#page12.tif
source=61755520#page13.tif
source=61755520#page14.tif
source=61755520#page15.tif
source=61755520#page16.tif
source=61755520#page17.tif
source=61755520#page18.tif

ASSIGNMENT

This Assignment Agreement is entered into by and between

1. Caroline EMERY citizen of United Kingdom Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA
2. Dale PORTER citizen of United States Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA
3. Lujian TAN citizen of United States Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA
4. Padmaja YERRAMILI-RAO, citizen of United Kingdom Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA

(hereinafter "Inventor(s)"), and Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, Novartis Institutes for BioMedical Research, Inc. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe

to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Institutes for BioMedical Research, Inc. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

PHARMACEUTICAL COMBINATIONS

and filed in the European Office on _____, 20____ and accorded Application Number _____ and/or filed as a PCT International Application on November 26 _____, 2013 and accorded International Patent Application Number PCT/ US2013/071852 _____; and/or filed in the United States Patent and Trademark Office on January 23, 2013 and accorded Application Number 61/755520;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for

and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 26ⁿ day of JUNE, 2013.

[Signature] L.S.
Caroline EMERY

[Signature]
Witness
Print Name: Kelli-Ann MONACO

[Signature]
Witness
Print Name: Linda Battalagine

Executed this _____ day of _____, 2013.

L.S.
Dale PORTER

Witness
Print Name:

Witness
Print Name:

Executed this 18ⁿ day of JUNE, 2013.

[Signature] L.S.
Lujian TAN

[Signature]
Witness
Print Name: QING SHENG

[Signature]
Witness
Print Name: FANG LI

Executed this 18 day of June, 2013.

L.S.
Padmaja YERRAMILI-RAO

Witness
Print Name:

Witness
Print Name:

Acceptance of Company
Executed this 10th day of September, 2013.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

BY: [Signature] L.S.
Print Name: [Signature]

[Signature]
Witness
Print Name: ASHA JENSON

[Signature]
Witness
Print Name: Jay Ghosh

ASSIGNMENT

This Assignment Agreement is entered into by and between

1. Caroline EMERY citizen of United Kingdom Novartis Institutes for
BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA

2. Dale PORTER citizen of United States Novartis Institutes for
BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA

3. Lujian TAN citizen of United States Novartis Institutes for
BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA

4. Padmaja YERRAMILI-RAO, citizen of United Kingdom Novartis Institutes for
BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA

(hereinafter "Inventor(s)"), and Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, Novartis Institutes for BioMedical Research, Inc. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe

to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Institutes for BioMedical Research, Inc. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

PHARMACEUTICAL COMBINATIONS

and filed in the European Office on _____, 20____ and accorded Application Number _____ and/or filed as a PCT International Application on November 26 _____, 2013 and accorded International Patent Application Number PCT/US2013/071852 _____; and/or filed in the United States Patent and Trademark Office on January 23, 2013 and accorded Application Number 61/755520;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for

and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____, 2013.

L.S.
Caroline EMERY

Witness
Print Name:


Witness
Print Name:

Executed this _____ day of _____, 2013.



L.S.
Dale PORTER

Witness
Print Name: Lance Aaron



Witness
Print Name: James Deeds

Executed this 21 day of June, 2013.

L.S.
Lujian TAN

Witness
Print Name:

Witness
Print Name:

Executed this _____ day of _____, 2013.

L.S.
Padmaja YERRAMILI-RAO

Witness
Print Name:

Witness
Print Name:

Acceptance of Company

Executed this 15th day of September, 2013.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

BY: [Signature] L.S.
Print Name: [Signature]

[Signature]
Witness
Print Name: Leslie Johnson

[Signature]
Witness
Print Name: Jay Chock

ASSIGNMENT

This Assignment Agreement is entered into by and between

- | | | |
|---------------------------|---------------------------|---|
| 1. Caroline EMERY | citizen of United Kingdom | Novartis Institutes for
BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA |
| 2. Dale PORTER | citizen of United States | Novartis Institutes for
BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA |
| 3. Lujian TAN | citizen of United States | Novartis Institutes for
BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA |
| 4. Padmaja YERRAMILI-RAO, | citizen of United Kingdom | Novartis Institutes for
BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139
USA |

(hereinafter "Inventor(s)"), and Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, Novartis Institutes for BioMedical Research, Inc. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe

to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Institutes for BioMedical Research, Inc. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

PHARMACEUTICAL COMBINATIONS

and filed in the European Office on _____, 20____ and accorded Application Number _____ and/or filed as a PCT International Application on November 26____, 2013 and accorded International Patent Application Number PCT/US2013/071852____; and/or filed in the United States Patent and Trademark Office on January 23, 2013 and accorded Application Number 61/755520;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for

and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____, 2013.

L.S.
Caroline EMERY

Witness
Print Name:

Witness
Print Name:

Executed this _____ day of _____, 2013.

L.S.
Dale PORTER

Witness
Print Name:

Witness
Print Name:

Executed this _____ day of _____, 2013.

L.S.
Lujian TAN

Witness
Print Name:

Witness
Print Name:

Executed this 8th day of July, 2013.

Padmaja YERRAMILLI-RAO
L.S.
Padmaja YERRAMILLI-RAO

Witness
Print Name: Tracey Marshall

Roger Davies

Witness
Print Name: Roger Davies

Acceptance of Company

Executed this 18th day of December, 2013.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

BY: [Signature] L.S.
Print Name: [Signature]

[Signature]
Witness
Print Name: Leslie Johnson

[Signature]
Witness
Print Name: Toy Chush

ASSIGNMENT

This Assignment Agreement is entered into by and between NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., 250 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA, a company organized under the laws of Delaware, and NOVARTIS AG, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. does hereby sell, assign and transfer to NOVARTIS AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

PHARMACEUTICAL COMBINATIONS

and filed in the European Office on _____, 20____ and accorded Application Number _____ and/or filed as a PCT International Application on November 26 _____, 2013 and accorded International Patent Application Number PCT/US2013/071852 _____; and/or filed in the United States Patent and Trademark Office on January 23, 2013 and accorded Application Number 61/755520;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other

international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e):

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. if this sale, assignment and transfer had not been made.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii)

make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 15th day of September, 2013.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

BY [Signature] L.S.

Print Name: [Signature]

Witness

Print Name: Leslie Jensen

Witness

Print Name: Jay Ghosh

Executed this 7th day of September, 2013.

NOVARTIS AG

BY Maurice McSee L.S.

Print Name: Maurice McSee, authorized signatory

Witness

Print Name: Paul K. Gallagher

Witness

Print Name: James Delaney

BY [Signature] L.S.

Print Name: Dennis Cooper, Authorized Signatory

Witness

Print Name: Paul K. Gallagher

Witness

Print Name: James Delaney